

WO 2024/050439 A2

- (51) International Patent Classification:
C07K 16/28 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2023/073194

(22) International Filing Date:
30 August 2023 (30.08.2023)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
63/402,945 31 August 2022 (31.08.2022) US

(71) Applicants: SYSTIMMUNE, INC. [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US). BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. [CN/CN]; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN).

(72) Inventors: HELGESON, Luke A.; 24240 SE 10th Pl., Sammamish, Washington 98075 (US). ROZANITIS, Tyler C.; 8501 Willows Road, Apt L268, Redmond, Washington 98052 (US). GOULET, Dennis R.; 6788 138th Ave
- NE #626, Redmond, Washington 98052 (US). KHALILI, Jahan; 12635 NE 130th Way #A103, Kirkland, Washington 98034 (US). DAVIS, Nicholas S.; 1425 Spring St. Apt 1406, Seattle, Washington 98104 (US). ZHU, Yi; 8-24, Building 6, No. 6, Lidu Road, Wuhou District, Chengdu, Sichuan (CN).
- (74) Agent: WAN, Feng; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: BIEPITOPIC TETRAVALENT ANTIBODY TARGETING EGFR



Antibody	Separate		Mixed	
	EC50 EGFRwt (nM)	EC50 EGFRvIII (nM)	EC50 EGFRwt (nM)	EC50 EGFRvIII (nM)
SI-95X54	78.22	15.30	13.33	15.08

(57) Abstract: A biepitopic tetraivalent antibody having a binding affinity to at least two epitopes of EGFR. The antibody comprises an antibody backbone and a scFv domain linked to the antibody backbone. The two epitopes of EGFR may include an EGFR wild-type (EGFRwt) epitope and an EGFRvIII epitope. The antibody has a stronger binding affinity to the EGFRvIII epitope than to the EGFRwt epitope.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*